Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 18/20 | 0.57 |
| ▸ | DDX3X | O00571 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033432 | 0.79 | SLC1A1 (0.51) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18472821 | 0.77 | ITGB1 (0.58) | ITGB1ITGA4DDX3X | |
| SCHEMBL29612679 | 0.77 | ITGB1 (0.67) | ITGB1ITGA4DDX3X | |
| SCHEMBL3485567 | 0.77 | ITGB1 (0.67) | ITGB1ITGA4DDX3X | |
| SCHEMBL29179632 | 0.76 | RAB9A (0.50) | ITGB1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14754438 | 0.76 | ITGB1 (0.63) | ITGB1ITGA4DDX3X | |
| SCHEMBL20808405 | 0.76 | ITGB1 (0.59) | ITGB1ITGA4DDX3X | |
| SCHEMBL8236504 | 0.75 | ITGB1 (0.56) | ITGB1ITGA4DDX3X | |
| SCHEMBL14528371 | 0.75 | ITGB1 (0.59) | ITGB1ITGA4 | |
| SCHEMBL7053184 | 0.74 | ITGB1 (0.69) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232868-A1 | Cyclic carboxylic acids as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2001058871-A1 | PIPERIDYL CARBOXYLIC ACIDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232868-A1 | Cyclic carboxylic acids as integrin antagonists | ITGA1, ITGB1, ITGA2B | ITGB1 2/4885ITGA4 17/4885DDX3X 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.